I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Treatment of skin cancers, cancers of oral cavity, oropharynx, and palate region by surface mold brachytherapy is a well-described technique in radiotherapy. The surface mold brachytherapy can be used alone.\[[@ref1][@ref2][@ref3]\] At MNJ Institute of Oncology and Regional Cancer Center, Red Hills, Hyderabad, Telangana, India, a total number of 7500 new cases are registered per year. Of which, 20% of cases are of head and neck region and majority (90%) of cases are in advanced stage at presentation. Early carcinomas of hard palate (Stage I) region account for less than 0.5% of early stages of head and neck cancers (10%) and rarely metastasize to regional lymph nodes.

Carcinomas of hard palate region account for less than 0.5% of head and neck region in MNJ Institute of Oncology and Regional Cancer Center. These tumors are easily accessible to vision, thereby to early diagnosis and treatment. External beam radiotherapy (EBRT) gives excellent results but it carries a longer duration of treatment. Surface mold brachytherapy is a practical mode of treatment and a good alternative to EBRT to the patients, where we can avoid multiple visits and prolonged duration of overall treatment duration. This is a practical way of treatment in centers where appropriate EBRT energies for treatment were not available.

Superficial cancers were reacted by Iridium (Ir)-192 interstitial brachytherapy\[[@ref4][@ref5]\] or with mold brachytherapy with gamma ray emitters.\[[@ref6]\] Nowadays, the present HDR brachytherapy machine uses a source, usually Ir-192, with few millimeters length and \<1 mm diameter and with high activity.\[[@ref7]\] High-dose-rate (HDR) brachytherapy equipment were accompanied by Treatment Planning System (TPS), calculation of dose distribution, and optimization for individual cases,\[[@ref8][@ref9][@ref10]\] thereby quality assurance and precision planning. In this article, we describe a custom-made low-cost HDR brachytherapy treatment technique useful in the treatment of six cases of hard palate carcinoma (T1N0M0).

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

We treated total six\[[@ref6]\] patients with T1 lesions of hard palate carcinoma between 2004 and 2009 at MNJ Institute of Oncology and Regional Cancer Center. The patients with histopathologically proven hard palate carcinoma were selected. After clinical examination, those having T1 lesions (as per tumor node metastasis staging system) without palpable neck nodes were included for protocol treatment. Contrast enhanced computed tomography (CECT) head and neck was carried out to exclude bone and paranasal sinus and lymph nodal involvement. Baseline blood investigations and chest X-Ray was carried out. After pre-radiotherapy dental prophylaxis and extractions, individual's hard palate impression was prepared with dental molding material for each patient. Tumor was traced on the mold. HDR source catheters were placed 0.8--1 cm apart based on the tumor size and with treatment, margin in the grooves was made manually and the flexible interstitial brachytherapy catheters were fixed in the grooves, which were parallel to each other. Before and after placing the catheters, dummy source checks were carried out to know the patency of the catheters. Dental mold with catheters was covered with dental wax to reduce discomfort to the patient. There is a problem with incisor teeth and anterior palate, causing some areas of irregularity of the arch of the surface, leading to smaller diameter tubes so as to pass the source to pass through the tubes. This will lead to a gap between channels and surface of the molds. The patients were simulated with intraoral wax mold and with dummy sources. The target volume was defined. Treatment planning and optimization were carried out with PLATO TPS. The patients were treated with a total dose of 42--45 Gy/14--15 fractions, with 3 Gy per fractions with two fractions per day with a minimum interval between two fractions being 6 h. The severity of oral mucosal reactions was recorded during treatment and after completion of treatment. During radiotherapy, patients were kept on mouth gargles and prophylactic oral antifungal. During treatment, patients who were experiencing pain because of mucosal reactions were given Xylocaine spray 5--10 min before placing mold. The minimum follow-up period was 2 years and maximum follow-up period was 5 years \[Figures [1](#F1){ref-type="fig"}--[6](#F6){ref-type="fig"}\].
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========================================================================

A total of six patients were studied, age of these patients ranged between 50 and 70 years. All of them had T1 lesions as per the inclusion criteria. One patient each had squamous cell carcinoma with histopathological grade 2 lesion and grade 3 lesion, whereas the remaining four patients had grade 1 lesion. These patients were followed up for 3--5 years and complete remission was seen in all the cases. All the patients received the radiation dose of 3 Gy per fraction with two fractions per day with minimum 6 h interval for 14--15 fractions over 10--14 days. None of the patients had a recurrence during the follow-up period. We produced an acceptable plan for all the six patients. The variation in the surface of lesions and the variation in implant distance lead to generate a plan, which delivers a uniform dose to the whole area.

###### 

Patient Characteristics

  Patient no.         1           2           3           4           5           6
  ------------------- ----------- ----------- ----------- ----------- ----------- -----------
  Age (years)         50          62          70          56          60          65
  T stage             T1          T1          T1          T1          T1          T1
  H.P Grade           1           3           1           2           1           1
  Follow up (Years)   5           5           3           4           4           5
  Response            CR          CR          CR          CR          CR          CR
  Dose Per \# (Gy)    3           3           3           3           3           3
  No of fractions     15          15          14          15          14          15
  Time (days)         12          10          14          11          12          12
  Mucocitis           confluent   confluent   confluent   Confluent   confluent   confluent

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Early cancers of the oral cavity can be effectively managed with surgery or radiation. Surgery will be in the form of wide local excision, leading to significant functional or cosmetic problems. Even it is very difficult to achieve negative margin. For early T1--2 oral cancers, combination of external beam radiation plus/minus brachytherapy boost usually in the form of interstitial brachytherapy had 74%--92% control rates.\[[@ref11][@ref12][@ref13]\] Sufficient evidence was available to prove that low-dose-rate (LDR) brachytherapy delivered higher doses of radiation for local control of oropharyngeal cancers and for limiting toxicity.\[[@ref14][@ref15][@ref16][@ref17]\] The local control and complication rates were similar with LDR and HDR brachytherapy.\[[@ref18][@ref19]\] To minimize morbidity, moderate doses of EBRT and smaller doses of HDR brachytherapy are used to prevent the wide spread lymphatic involvement. In the present study of hard palate carcinoma with minimal lymph node involvement, HDR mold barchytherapy was used more effectively. In 2004, before initiating treatment, we communicated with Subir Nag, regarding evidence of using HDR brachytherapy as a sole modality for dosage schedule.\[[@ref20]\] In selected patients with early and superficial lesions, the use of surface mold applicators has advantages such as avoiding surgical procedures and its sequelae, treatment on outpatient basis, and reduction in an overall treatment time of 10--14 days as compared to 6--8 weeks when compared to that of external beam radiation treatment. This option is particularly useful for elderly patients and patients with poor performance status. Follow-up examination can detect a local recurrence at the earliest and surgical salvage can be carried out without much more complications as we can limit high-dose volume by brachytherapy. Even we can reserve external beam radiation as an option for second primaries of head and neck.\[[@ref21]\]

The cost of HDR brachytherapy equipment is much lower than the cost of linear accelerators with intensity modulated radiotherapy or three-dimensional conformal radiotherapy and both the facilities were not available at MNJ Institute of Oncology and Regional Cancer Center during the study period. The mold materials used were the cheapest. Hence, this is a low-cost and effective therapy.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

The radiotherapy is equally effective in the treatment of early hard palate carcinomas. The HDR mold brachytherapy with custom-made applicators will be helpful in uniform dose distribution to the tumor with sharp fall of dosage at the edges of the applicators. Use of custom-made mold was reproducible for daily treatment and helpful for high-precision treatment, thereby achieving excellent local control, mucosal complications comparable to that of EBRT, less overall treatment duration, which can be carried out on outpatient department basis, and low cost as compared to conformal therapies.
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